Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Inhaled Treprostinil Transition from Ventavis
NCT00741819Phase 4Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Sep 2008
- Primary completion
- Mar 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Primary endpoint: Number of Adverse Events at 24 months. Started Sep 2008; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00741819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00741819.